The global axial spondyloarthritis drugs market is anticipated to grow at a significant CAGR during the forecast period (2021-2027). Axial spondyloarthritis is a type of inflammatory arthritis. It primarily affects the spine and the sacroiliac (SI) joints that are connected to the lower spine to the pelvis which results in pain in the lower back, hips, and buttocks. The major factor driving the growth of the market is the new product launches and drug approval across the globe.
For instance, in August 2019, Eli Lilly and Company announced the approval of Taltz (ixekizumab) injection 80 mg/mL from the US Food and Drug Administration (FDA). It is used for the treatment of active ankylosing spondylitis (AS) which is also known as radiographic axial spondyloarthritis (r-axSpA) in adults. Additionally, in June 2020, Novartis announced the approval of Cosentyx (secukinumab) from the US Food and Drug Administration (FDA). It is used for the treatment of active non-radiographic axial spondyloarthritis (nr-axSpA).
Some major players in the market include AbbVie Inc., Novartis International AG, and Johnson & Johnson, among others. The market players are contributing significantly to the growth of the market by the adoption of various strategies including mergers & acquisitions, geographical expansion, partnerships and collaborations, and new product launches, to stay competitive in the market. For instance, in January 2022, AbbVie announced the submission of applications to seek approvals for upadacitinib (RINVOQ, 15 mg) to the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). Upadacitinib (RINVOQ, 15 mg) is used for the treatment of active non-radiographic axial spondyloarthritis (nr-axSpA) with objective signs of inflammation in adults who have responded inadequately to nonsteroidal anti-inflammatory drugs (NSAIDs).
Market Coverage
• The market number available for – 2020-2027
• Base year- 2020
• Forecast period- 2021-2027
• Segment Covered-
o By Type
o By Application
• Regions Covered-
o North America
o Europe
o Asia-Pacific
o Rest of the World
• Competitive Landscape- AbbVie Inc., Novartis International AG, and Johnson & Johnson Services, Inc., among others.
Key questions addressed by the report
• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• How has COVID-19 impacted the market?
o Deviation from the pre-COVID-19 forecast
o Most affected region and segment
• Who is the leader in the market?
• How players are addressing challenges to sustain growth?
• Where is the investment opportunity?
Global Axial Spondyloarthritis Drugs Market Report by Segment
By Type
• Certolizumab Pegol
• Etanercept Biosimilar
• Ixekizumab
• Secukinumab
• Others
By Application
• Clinic
• Hospital
• Homecare
Global Axial Spondyloarthritis Drugs Market Report by Region
North America
• United States
• Canada
Europe
• UK
• Germany
• Italy
• Spain
• France
• Rest of Europe
Asia-Pacific
• China
• India
• Japan
• South Korea
• Rest of Asia-Pacific
Rest of the World
• Latin America
• Middle East & Africa